



December 29, 2023

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

Scrip code: 532531

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai – 400 051

Scrip code: STAR

Dear Madam/ Sir,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR')**

**Ref: Update on Sale of Manufacturing Facility in Singapore**

We refer to the press release issued by the Company on October 27, 2023 titled 'Strides announces sale of manufacturing facility in Singapore for a consideration of \$15m' and disclosure under Regulation 30 of SEBI LODR on the transaction.

In continuation to the above, we wish to inform you that the transaction has achieved closure today for a total consideration of \$15m. Strides Pharma Global Pte. Limited, Singapore has received \$12m as part of closing and the remaining consideration of \$3m will be received in Q2 FY25.

The entire proceeds will be used to pare down debts.

This is for your information and records.

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
**Company Secretary**  
**ICSI Membership No.: A30515**

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700  
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942  
corpcomm@strides.com, www.strides.com